ChromaDex: Difference between revisions
Content deleted Content added
Hathatehat (talk | contribs) m →BluScience and pTeroPure: fixed citation |
SVG logo |
||
| (134 intermediate revisions by 59 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Food ingredient company in California}} |
|||
{{Infobox company |
{{Infobox company |
||
| |
| name = ChromaDex, Inc |
||
| logo = ChromaDex_logo.svg |
|||
| company_logo = |
|||
| |
| type = [[Public company|Public]] |
||
| traded_as |
| traded_as = {{NASDAQ|CDXC}}<br />[[Russell 2000 Index]] component |
||
| industry = [[Dietary supplements]], food ingredients, chemical sample analysis |
|||
| foundation |
| foundation = 1999 |
||
| location |
| location = [[Los Angeles, California]], United States |
||
| key_people = [[Frank Jaksch]]<br><small>([[Co-Founder]], CSO |
|||
| key_people = [[Rob Fried]]<br /><small>(CEO)</small><br />Frank Jaksch<br /><small>(Cofounder, Executive Chairman)</small> |
|||
| industry = [[Pharmaceutical company|Pharmaceuticals]] |
|||
| products |
| products = Tru Niagen |
||
| |
| website = {{URL|https://www.chromadex.com/}} |
||
}} |
}} |
||
'''ChromaDex''' is a [[dietary supplement]] and [[food ingredient]] company based in [[Los Angeles, California]] founded in 1999 that is publicly traded on the NASDAQ. |
|||
'''ChromaDex''' is a [[publicly traded]] natural products company based in [[Irvine, California]]. The company is most well-known for its industry standard phytochemical testing laboratories and catalogue. In cooperation with the [[University of Mississippi]], the company is currently exploring the effects of pterostiibene on humans.<ref name="S&P">{{cite web |url= http://reports.finance.yahoo.com/w0?r=51045923:2 |title= ChromaDex: Standard & Poor's Factual Report |accessdate=2012-05-20 |last=Standard & Poor's|first= |coauthors= |date=2012 |work= |publisher=Standard & Poors |pages=11 |quote= }}</ref> |
|||
ChromaDex |
In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref> |
||
== History == |
|||
In 2010, ChromaDex won the North American Frost & Sullivan Award for Most Promising Ingredient of the Year for pTeroPure pterostilbene.<ref name="FS">{{cite web |url= http://finance.yahoo.com/news/Frost-Sullivan-Recognizes-iw-3192305786.html?x=0 |title= Frost & Sullivan Recognizes ChromaDex for the Unique Potential Its Commercially Available Product Offers in the Human Nutrition Industry |accessdate=2012-05-25 |last=|first= |coauthors= |date=5-3-2011 |work= |publisher=Yahoo Finance |pages= |quote= }}</ref><ref name="S&P"/> |
|||
Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013. |
|||
ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018. |
|||
American billionaire and pharmaceutical [[entrepreneur]] [[Phillip Frost]] owns approximately 19% of ChromaDex.<ref name="TREFIS1">{{cite web |url= http://www.trefis.com/stock/pfe/articles/123353/billionaire-phillip-frost-a-case-study-in-synergy/2012-05-28?from=filmstrip%3Atop |title= Billionaire Phillip Frost: A Case Study In Synergy |accessdate=2012-05-29 |last=Gould|first=David |coauthors= |date=5-3-2011 |work= |publisher=TREFIS |pages= |quote= }}</ref><ref name="CHROMADEX2">{{cite web |url= https://www.chromadex.com/NewsEventDetail.aspx?Aid=532 |title= ChromaDex Corp. Names Consumer Products Veteran Jeffrey Himmel CEO |accessdate=2012-05-29 |last=Gould|first=David |coauthors= |date=1-23-2012 |work= |publisher= |pages= |quote= }}</ref><ref name="S&P"/> |
|||
In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development. |
|||
==Early history== |
|||
| ⚫ | |||
Chromadex was founded in 1999. According to a [[Standard & Poor's]] research report, the company was created "in response to growing demand for natural product reference standards, materials and services. It has worked to establish itself as an industry leader in nutraceutical and botanical certification, and even publishes its own manual outlining specifications for phytochemicals." On July 14, 2008 ChromaDex merged with CDI Acquisition, a subsidiary of Cody Resources Inc. On July 29, 2008 the company completed a private placement agreement, which yielded gross proceeds of $4.67 million.<ref name="CHROMADEX">{{cite web |url= https://chromadex.com/NewsEventDetail.aspx?Aid=35 |title= Functional Ingredients |accessdate=2012-05-29 |last=|first= |coauthors= |date=5-10-2009 |work= |publisher= |pages= |quote= }}</ref><ref name="S&P"/> |
|||
{{Reflist}} |
|||
==External links== |
|||
Later in 2008, Chromadex (OTCBB: CDXC) became a publicly traded company. Shares of Chromadex are traded on the NASD Over-The-Counter Bulletin Board.<ref name="S&P"/> |
|||
* {{Official website|http://www.chromaDex.com}} |
|||
{{Authority control}} |
|||
==ChromaDex catalogue== |
|||
[[Category:Biotechnology companies of the United States]] |
|||
The ChromaDex catalogue "provides [[phytochemical]] reference standards, botanical reference materials and research grade materials for the natural products industry." The company sells over 3,000 phytochemicals and 470 [[botanical]] reference materials in its catalogue. The company's products reach a wide range of markets including food & beverage, pharmaceutical, [[cosmeceutical]], research organizations and governmental groups.<ref name="S&P"/> |
|||
[[Category:Pharmaceutical companies of the United States]] |
|||
[[Category:Pharmaceutical companies established in 1999]] |
|||
==BluScience and pTeroPure== |
|||
[[Category:Companies based in Irvine, California]] |
|||
[[Category:Biotechnology companies established in 1999]] |
|||
Chromadex received exclusive worldwide patent rights for its pTeroPure pterostilbene product based on the technology licensed from the University of Mississippi and the USDA.<ref name="S&P"/> Similar to [[resveratrol]], which the [[Mayo Clinic]] describes as "a key ingredient in [[red wine]] that helps prevent damage to blood vessels, reduces "bad" cholesterol and prevents blood clots"<ref name="MAYO">{{cite web |url= http://www.mayoclinic.com/health/red-wine/hb00089 |title= Red wine and resveratrol: Good for your heart? |accessdate=2012-05-29 |last=Mayo Clinic Staff|first= |coauthors= |date=3-4-2011 |work= |publisher=Mayo Clinic |pages= |quote= }}</ref><ref name="S&P"/> pterostilbene belongs to a class of compounds called phytoalexins, which are antimicrobial substances synthesized de novo by plants that accumulate rapidly at areas of incompatible pathogen infection. Based on animal studies pterostilbene is thought to exhibit anti-cancer, anti-hypercholesterolemia, anti-hypertriglyceridemia properties, as well as fight off and reverse cognitive decline.<ref name="webmd">[http://www.webmd.com/content/article/19/1728_50062.htm Braslavsky, Andrea, "Blueberries May Be King of the Hill for Those Over the Hill," WebMD Medical News, Sept. 16, 1999, retrieved December 29, 2006.]</ref><ref name="S&P"/> |
|||
[[Category:1999 establishments in California]] |
|||
[[Category:Health care companies based in California]] |
|||
Pterostilbene and resveratrol have similar pharmacologic properties. However pterostilbene has exhibited advantages over resveratrol including superior biological activity, better oral [[bioavailability]], and a slower metabolizing time, which provides more time for the compound's antioxidant activities to act.<ref name="S&P"/><ref name=ccp>{{cite journal | author=IM Kapetanovic et al|title=Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats| journal=Cancer Chemother Pharmacol | pmid= 21116625| doi=10.1007/s00280-010-1525-4| year=2010| month=November | volume=68 | issue=3 | pages=593–601 | pmc=3090701}}</ref><ref name=pr>{{cite journal | author=CM Remsberg et al|title=Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity| journal=Phytother Res | pmid= 17726731| doi=10.1002/ptr.2277| volume=22| issue=2| year=2008| month=February| pages=169–79}}</ref><ref name=neo>{{cite journal | author= P Ferrer et al|title=Association between Pterostilbene and Quercetin Inhibits Metastatic Activity of B16 Melanoma | journal=Neoplasia | pmid= 15736313 | volume=7 | issue=1 | pmc=1490314 | year=2005 | month=January | pages=37–47}}</ref> |
|||
According to the [[USDA]], "pterostilbene is one of many aromatic hydrocarbons called 'stilbenes.'' Chromadex's pTeroPure is an identical form of trans-pterostilbene.<ref name="USDA">{{cite web |url= www.ars.usda.gov/is/AR/archive/nov06/health1106.htm?pf=1 |title= Pterostilbene’s Healthy Potential |accessdate=2012-05-29 |last=Pons|first=Luis |coauthors= |date= |work= |publisher=USDA |pages= |quote= }}</ref><ref name="S&P"/> |
|||
The [[University of California, Irvine]], is currently studying pTeroPure for its efficacy as a treatment for melanomas and other skin cancers when used in a skincare product.<ref name="NO">{{cite web |url= http://www.nutritionaloutlook.com/article/best-2011-ingredient-supplier-chromadex-4-8431 |title= Best of 2011 Ingredient Supplier: ChromaDex |accessdate=2012-05-29 |last=|first= |coauthors= |date= |work= |publisher=Nutritional Outlook |pages= |quote= }}</ref> |
|||
| ⚫ | |||
{{reflist}} |
|||
Latest revision as of 08:17, 19 October 2024
 | |
| Company type | Public |
|---|---|
| Nasdaq: CDXC Russell 2000 Index component | |
| Industry | Dietary supplements, food ingredients, chemical sample analysis |
| Founded | 1999 |
| Headquarters | Los Angeles, California, United States |
Key people | Rob Fried (CEO) Frank Jaksch (Cofounder, Executive Chairman) |
| Products | Tru Niagen |
| Website | www |
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.
In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure.[1] ChromaDex no longer sells pTeroPure.[2]
History
[edit]Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013.
ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.
In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development.
References
[edit]- ^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.
- ^ Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.
